|
|
Vernalis Plc - Comparative Business Analysis Snapshot
Business Description
Vernalis Plc. The Group's principal activity is to develop and commercialize pharmaceutical products for a range of medical disorders. It has expertise both in de- novo structure and fragment-based drug discovery and pre-clinical and clinical development. The Group has seven product candidates in clinical development (two of which are partnered), two programmes in pre-clinical (one with a partner) and other competitive research programmes. The Group operates in the United Kingdom, Rest of Europe, North America and Rest of the World. On 01-Jul-2008, the Group completed the sale of Apokyn and Vernalis Pharmaceuticals Inc.
Competitor Analysis
This analysis compares Vernalis Plc with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
